Trogenix
Transforming cancer treatment paradigms
- Employees
- 1–10
- Business Model
- B2B
- Website
- trogenix.com
- Total Funding
- $107.5M
- Last Round
- $95.0M Series AOct 2025
- Rounds
- 2
About
Trogenix is a cancer therapy company pioneering precision genetic medicines using proprietary Synthetic Super-Enhancer (SSE) technology delivered via AAV vectors. Its Odysseus platform selectively targets aggressive solid tumours — beginning with glioblastoma — by leveraging transcription factors unique to cancer cells to trigger immune-mediated tumour destruction. The company aims to deliver curative, one-and-done therapies for patients with devastating cancers.
Summary
Trogenix is a Biotech company. It has raised $107.5M in total across 2 rounds, most recently a $95.0M Series A round in Oct 2025. Investors include IQ Capital Partners and 4BIO Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Oct 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.